ArticleProceedings of the National Academy of Sciences of the United States of America2015

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.

Linda Henneman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.